Trading Strategy
Last Price@717
Plan A
Expect Bullish Move "If" stock holds in 705-709 zone with strict stops below 695
Targets- 760/775/790
Plan B
Sell Below 695 with strict stops above 720
Target - 620 / 630
Thanks for watching the video.
In daily time frame its attempting to enter into Kumo with a probable IHS formation. In weekly time frame its attempting a C Clamp structure. Has good support near 570-580 and immediate resistance at 605-610. Above that 675 is the next major resistance.
AUROBINDO PHARMA HOUR CHART INDICATES AN INVERTED H&S IN FORMATION WITH NECK LINE AT 622 LVL.
ONCE THIS IS CROSSED THEN NEXT TARGETS ARE 628 / 634 & 655.
LET THE SHARE TRADE ABOVE 608. THEN ONE CAN ENTER WITH A PROPER STOP LOSS.
AURO PHARMA - In EST , likely to move down to 595 , 589 , 582.
Can look for short up to 609 break of 603
With SL above 614
Validity: This view INVALID if scrip moves above 614.
NSE:AUROPHARMA
DISCLAIMER: I am not a certified Technical analyst. Please do your own analysis before taking any Investment/Trading decisions.
LEVELS ON CHART
B = BUY ABOVE
S = SELL BELOW
T = TARGET
BOOK 70% ON FIRST TARGET REST TRAIL
View for educational purpose only trade according to your rules and analysis
AUROPHARMA, Aurobindo Pharma Ltd had given breakout for Flag chart pattern. Definitely, it will be bullish.
Entry : 595
Stop Loss: 584
Target: ~660
I hope, we will get this target less than 5 to 6 weeks.
Regards,
Vikram
GO SHORT, MEDIUM AND LONG INVESTMENT PURPOSE
BUY NEAR 550
STOP LOSS 528
Disclaimer: All posts/views are for educational purpose only..!!
Kindly contact financial advisor before taking position/decision.
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
AUROPHARMA
